Components	O
of	O
treatment	B:C0087111
delay	O
in	O
rheumatoid	B:C0003873
arthritis	I:C0003873
differ	O
according	O
to	O
autoantibody	B:C0004358
status	O
:	O
validation	B:C1519941
of	O
a	O
single	O
-	O
centre	O
observation	O
using	O
national	O
audit	O
data	O
.	O

To	O
determine	O
whether	O
time	O
to	O
treatment	O
following	O
symptom	O
onset	O
differs	O
between	O
RA	B:C0003873
patients	O
according	O
to	O
autoantibody	B:C0004358
status	O
.	O

A	O
single	O
-	O
centre	O
retrospective	O
analysis	B:C0936012
of	O
a	O
UK	B:C0041700
early	O
RA	B:C0003873
inception	O
cohort	O
was	O
first	O
undertaken	O
to	O
identify	O
those	O
components	O
of	O
the	O
patient	O
journey	O
that	O
differed	O
by	O
serological	O
subtype	B:C0449560
.	O

Data	O
from	O
a	O
UK	B:C0041700
national	O
audit	O
of	O
early	O
inflammatory	B:C0003864
arthritis	I:C0003864
patients	O
was	O
accessed	B:C0444454
to	O
replicate	O
the	O
key	O
finding	B:C0243095
.	O

A	O
total	O
of	O
173	O
RA	B:C0003873
patients	O
were	O
diagnosed	B:C0430022
over	O
a	O
31	O
-	O
month	O
period	O
,	O
of	O
whom	O
80	O
(	O
46	O
%	O
)	O
were	O
ACPA	O
/	O
RF	O
double	O
-	O
seropositive	O
(	O
ACPA	O
(	O
+	O
)	O
/	O
RF	O
(+	O
)	O
)	O
,	O
53	O
(	O
31	O
%	O
)	O
ACPA	O
(-)/RF	O
(-)	O
,	O
17	O
(	O
10	O
%	O
)	O
ACPA	O
(+)/	O
RF	O
(-)	O
and	O
23	O
(	O
13	O
%	O
)	O
RF	O
(+)	O
/	O
ACPA	O
(-)	O
Overall	O
,	O
ACPA	O
(+)	O
/	O
RF	O
(+)	O
patients	O
experienced	O
significantly	O
longer	O
symptom	O
duration	O
before	O
DMARD	B:C0242708
initiation	O
.	O

This	O
was	O
accounted	O
for	O
by	O
delays	O
in	O
their	O
presentation	O
to	O
primary	B:C0033137
care	I:C0033137
following	O
symptom	O
onset	O
-	O
a	O
finding	B:C0243095
that	O
was	O
robustly	O
confirmed	O
in	O
an	O
independent	O
dataset	B:C0150098
of	O
2192	O
UK	B:C0041700
early	O
RA	B:C0003873
patients	O
.	O

In	O
contrast	O
,	O
ACPA	O
(	O
-)	O
/	O
RF	O
(-)	O
patients	O
were	O
significantly	O
more	O
likely	O
to	O
experience	O
delays	O
in	O
DMARD	B:C0242708
initiation	O
after	O
presenting	O
to	O
secondary	B:C3494402
care	I:C3494402
.	O

Causes	O
of	O
treatment	B:C0087111
delays	O
in	O
early	O
RA	B:C0003873
differ	O
according	O
to	O
patients	O
'	O
autoantibody	B:C0004358
status	O
.	O

More	O
insidious	O
symptom	O
onset	O
and	O
/	O
or	O
distinct	O
health	O
-	O
seeking	O
behaviours	O
among	O
ACPA	O
(+	O
)	O
/	O
RF	O
(+)	O
patients	O
may	O
contribute	O
to	O
late	O
presentations	O
in	O
primary	B:C0033137
care	I:C0033137
,	O
whereas	O
ACPA	O
(	O
-)	O
/	O
RF	O
(-)	O
patients	O
experience	O
delayed	O
diagnosis	O
and	O
treatment	B:C0087111
in	O
secondary	B:C3494402
care	I:C3494402
.	O

These	O
observations	O
inform	B:C0700287
the	O
research	O
agenda	O
,	O
potentially	O
influencing	O
the	O
design	O
of	O
service	B:C0011211
delivery	I:C0011211
for	O
early	B:C3899278
arthritis	I:C3899278
patients	O
.	O

